Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: AB Volvo

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

AB Volvo: Announces June 25 its plans to offer 46 mil. shares of Pharmacia & Upjohn stock -- about two thirds of Volvo's stake in the company -- valued at almost $2 bil. Underwriters will have the option to purchase an additional 6.9 mil. shares to cover possible over allotments. Volvo expects to price the stock offering by the week of July 22. To protect its interest in divesting its stake in Pharmacia & Upjohn, Volvo apparently blocked the company's efforts to acquire Allergan in May ("The Rose Sheet" May 20, In Brief)...

Table

View full table

Tags:
Latest Headlines

AI Used In Drug R&D Likely Exempt From Tough EU AI Rules, Says EFPIA

EU Parliament OKs New Rules On Use Of Patient Data In Research

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

See All
UsernamePublicRestriction

Register

RS002974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By